清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

医学 吡非尼酮 特发性肺纤维化 安慰剂 双盲 内科学 间质性肺病 胃肠病学 肺纤维化 病理 替代医学
作者
Jürgen Behr,Antje Prasse,Michael Kreuter,Johannes Johow,Klaus F. Rabe,Francesco Bonella,R. Bonnet,Christian Grohé,Matthias Held,Heinrike Wilkens,Peter Hammerl,Dirk Koschel,Stefan Blaas,Hubert Wirtz,Joachim H. Ficker,Wolfgang Neumeister,Nicolas Schönfeld,Martin Claussen,Nikolaus Kneidinger,Marion Frankenberger
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (5): 476-486 被引量:398
标识
DOI:10.1016/s2213-2600(20)30554-3
摘要

Pirfenidone has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive fibrotic interstitial lung diseases (ILDs)) other than IPF. In view of the pathomechanistic and clinical similarities between IPF and other progressive fibrotic ILDs, we aimed to assess the efficacy and safety of pirfenidone in patients with four non-IPF progressive fibrotic ILDs.We did a multicentre, double-blind, randomised, placebo-controlled, parallel phase 2b trial (RELIEF) in 17 centres with expertise in ILD in Germany. Eligible participants were patients aged 18-80 years with progressive fibrotic ILD due to four diagnoses: collagen or vascular diseases (ie, connective tissue disease-associated ILDs), fibrotic non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, or asbestos-induced lung fibrosis. Other eligibility criteria included a forced vital capacity (FVC) of 40-90% predicted, a diffusing capacity of the lung for carbon monoxide of 10-90% predicted, and an annual decline of FVC of at least 5% predicted despite conventional therapy, based on at least three measurements within 6-24 months before enrolment. Patients who had received any previous antifibrotic therapy were excluded. We randomly assigned patients (1:1) to either oral pirfenidone (267 mg three times per day in week 1, 534 mg three times per day in week 2, and 801 mg three times per day thereafter) or matched placebo, added to their ongoing medication. Randomisation was done centrally using permuted block randomisation with varying block sizes stratified by the four diagnostic groups. Patients, investigators, statisticians, monitors, and the study coordinator were masked to treatment assignment until database closure. The placebo-controlled study period was 48 weeks (including up-titration). The primary endpoint was absolute change in percentage of predicted FVC (FVC % predicted) from baseline to week 48 in the intention-to-treat population, with imputation of missing data by the smallest sum of squared differences and attribution of deceased patients to the lowest rank in a rank ANCOVA model. Additionally, we did linear mixed-model repeated measures slope analyses of FVC % predicted longitudinal data over the course of the study as a prespecified sensitivity analysis and post-hoc sensitivity analyses of the primary endpoint in the intention-to-treat population using imputation methods of last observation carried forward [LOCF] and a regression-based multiple imputation procedure. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered with EudraCT 2014-000861-32; DRKS00009822 and is no longer recruiting.Between April 5, 2016, and Oct 4, 2018, we randomly assigned 127 patients to treatment: 64 to pirfenidone, 63 to placebo. After 127 patients had been randomised, the study was prematurely terminated on the basis of an interim analysis for futility triggered by slow recruitment. After 48 weeks and in the overall population of 127 patients, rank ANCOVA with diagnostic group included as a factor showed a significantly lower decline in FVC % predicted in the pirfenidone group compared with placebo (p=0·043); the result was similar when the model was stratified by diagnostic group (p=0·042). A significant treatment effect was also observed when applying the LOCF and multiple imputation methods to analyses of the primary endpoint. The median difference (Hodges-Lehmann estimate) between pirfenidone and placebo groups for the primary endpoint was 1·69 FVC % predicted (95% CI -0·65 to 4·03). In the linear mixed-model repeated measures slope analysis of FVC % predicted, the estimated difference between treatment and placebo groups from baseline to week 48 was 3·53 FVC % predicted (95% CI 0·21 to 6·86) with imputation of deaths as prespecified, or 2·79 FVC % predicted (95% CI 0·03 to 5·54) without imputation. One death (non-respiratory) occurred in the pirfenidone group (2%) and five deaths (three of which were respiratory) occurred in the placebo group (8%). The most frequent serious adverse events in both groups were infections and infestations (five [8%] in the pirfenidone group, ten [16%] in the placebo group); general disorders including disease worsening (two [3%] in the pirfenidone group, seven [11%] in the placebo group); and cardiac disorders (one ([2%] in the pirfenidone group, 5 [8%] in the placebo group). Adverse events (grade 3-4) of nausea (two patients on pirfenidone, two on placebo), dyspnoea (one patient on pirfenidone, one on placebo), and diarrhoea (one patient on pirfenidone) were also observed.In view of the premature study termination, results should be interpreted with care. Nevertheless, our data suggest that in patients with fibrotic ILDs other than IPF who deteriorate despite conventional therapy, adding pirfenidone to existing treatment might attenuate disease progression as measured by decline in FVC.German Center for Lung Research, Roche Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三应助科研通管家采纳,获得10
2秒前
科目三应助科研通管家采纳,获得10
3秒前
6秒前
七人七发布了新的文献求助10
8秒前
小王发布了新的文献求助20
11秒前
共享精神应助王月缶采纳,获得30
12秒前
ChatGPT完成签到,获得积分10
13秒前
我和你完成签到 ,获得积分10
16秒前
万能图书馆应助小王采纳,获得10
18秒前
19秒前
量子星尘发布了新的文献求助10
20秒前
王月缶完成签到,获得积分10
21秒前
23秒前
王月缶发布了新的文献求助30
24秒前
不知道完成签到,获得积分10
26秒前
闪闪的谷梦完成签到 ,获得积分10
38秒前
43秒前
jjjjjj发布了新的文献求助10
44秒前
jcomeon123完成签到,获得积分10
48秒前
ggg完成签到 ,获得积分10
1分钟前
东郭凝蝶完成签到 ,获得积分10
1分钟前
lida发布了新的文献求助10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
digger2023完成签到 ,获得积分10
1分钟前
gwbk完成签到,获得积分10
1分钟前
1分钟前
1分钟前
雪山飞龙发布了新的文献求助10
1分钟前
小王发布了新的文献求助10
1分钟前
辣辣辣辣辣辣完成签到 ,获得积分10
1分钟前
mojito完成签到 ,获得积分10
1分钟前
JJ完成签到 ,获得积分10
1分钟前
yeurekar发布了新的文献求助10
1分钟前
Ava应助小王采纳,获得10
1分钟前
谭玲慧完成签到 ,获得积分10
1分钟前
KINGAZX完成签到 ,获得积分10
1分钟前
无花果应助科研通管家采纳,获得10
2分钟前
何pulapula完成签到 ,获得积分10
2分钟前
yeurekar完成签到,获得积分10
2分钟前
济民财完成签到,获得积分10
2分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4008607
求助须知:如何正确求助?哪些是违规求助? 3548284
关于积分的说明 11298733
捐赠科研通 3282975
什么是DOI,文献DOI怎么找? 1810274
邀请新用户注册赠送积分活动 885976
科研通“疑难数据库(出版商)”最低求助积分说明 811218